Trial Profile
To investigate association between Regorafenib induced adverse events and efficacy in patients with metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2017
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Mar 2017 New trial record
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium